A Retrospective Cohort Study of Transgender Adolescents' Gender-Affirming Hormone Discontinuation
January 2025
in “
Journal of Adolescent Health
”
Studysummary In this retrospective cohort study, researchers found that persistent discontinuation of gender-affirming hormones among transgender adolescents was rare, mainly due to achieving gender expression goals or access issues, with very few reidentifying with their birth-assigned sex.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
This retrospective cohort study examined the discontinuation of gender-affirming hormones (GAH) among transgender adolescents. Out of 1,050 eligible individuals, 93% continued GAH at last contact, while 4% discontinued without restarting. Only 0.5% reidentified with their birth-assigned gender. The study concludes that persistent discontinuation is rare and often due to achieving gender expression goals or access issues, rather than detransitioning. Future research should focus on understanding the reasons for discontinuation without assuming detransition or regret.
